Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma II

ABSTRACT: To investigated how CD4 T cells change in the development of hepatocelluar carcinoma We then performed gene expression profiling analysis using data obtained from RNA-seq of CD4 T cells

ORGANISM(S): Mus musculus

PROVIDER: GSE242164 | GEO | 2024/05/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

Project description:To investigated how Matr3 KO affected the function of CD4 T cells We then performed gene expression profiling analysis using data obtained from RNA-seq of Jurkat T cells knocked out of Matr3 or not.

2024-05-29 | GSE234457 | GEO

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

Project description:To investigated how Matr3 KO affected the function of CD4 T cells We then performed gene expression profiling analysis using data obtained from Hi-C seq of Jurkat T cells knocked out of Matr3 or not.

2024-05-29 | GSE239507 | GEO

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma II

Project description:Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma II

| PRJNA1011889 | ENA

Hepatocellular carcinoma specific epigenetic checkpoint bi-directionally regulates antitumor immunity of CD4+T cell

Project description:To investigate the effect of Matr3 CKO of CD4+ T cells on HCC of mice.

2024-05-29 | GSE263391 | GEO

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

Project description:Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

| PRJNA981474 | ENA

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

Project description:Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

| PRJNA999609 | ENA

Hepatocellular carcinoma specific epigenetic checkpoint bi-directionally regulates antitumor immunity of CD4+T cell

Project description:Hepatocellular carcinoma specific epigenetic checkpoint bi-directionally regulates antitumor immunity of CD4+T cell

| PRJNA1097278 | ENA

Fucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: CD4+ T Cell Phosphoproteomics

Project description:Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with other modalities have yielded limited improvements but also adverse events requiring cessation of treatment. In addition to ineffective patient stratification, efficacy is impaired by paucity of intratumoral immune cells (itICs)—thus, effective strategies to safely increase itICs are needed. We report that dietary administration of L-fucose induces fucosylation and cell surface enrichment of the MHC-II protein HLA-DRB1 in melanoma cells, triggering CD4+T cell-mediated increases in ItICs and anti-tumor immunity, enhancing immune checkpoint blockade responses. Melanoma fucosylation and fucosylated HLA-DRB1 associate with intratumoral T cell abundance and anti-PD1 responder status in patient melanoma specimens, suggesting the potential use of melanoma fucosylation as a strategy for stratifying patients for immunotherapies. Our findings demonstrate that fucosylation is a key mediator of anti-tumor immunity, and importantly, suggest that L-fucose is a powerful agent for safely increasing ItICs and immunotherapy efficacy in melanoma.

2022-12-16 | PXD038065 | Pride

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.

Project description:Hepatocellular carcinoma (HCC) constitutes most primary liver cancers and is one of the most lethal and life-threatening malignancies globally. Unfortunately, a substantial proportion of HCC patients are identified at an advanced stage that is unavailable for curative surgery. Thus, palliative therapies represented by multi-tyrosine kinase inhibitors (TKIs) sorafenib remained the front-line treatment over the past decades. Recently, the application of immune checkpoint inhibitors (ICIs), especially targeting the PD-1/PD-L1/CTLA-4 axis, has achieved an inspiring clinical breakthrough for treating unresectable solid tumors. However, many HCC patients with poor responses lead to limited benefits in clinical applications, which has quickly drawn researchers' attention to the regulatory mechanisms of immune checkpoints in HCC immune evasion. Evasion of immune surveillance by cancer is attributed to intricate reprogramming modulation in the tumor microenvironment. Currently, more and more studies have found that epigenetic modifications, such as chromatin structure remodeling, DNA methylation, histone post-translational modifications, and non-coding RNA levels, may contribute significantly to remodeling the tumor microenvironment to avoid immune clearance, affecting the efficacy of immunotherapy for HCC. This review summarizes the rapidly emerging progress of epigenetic-related changes during HCC resistance to ICIs and discusses the mechanisms of underlying epigenetic therapies available for surmounting immune resistance. Finally, we summarize the clinical advances in combining epigenetic therapies with immunotherapy, aiming to promote the formation of immune combination therapy strategies.

| S-EPMC9845774 | biostudies-literature

Fucosylation of HLA-DRB1 regulates CD4+T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy: Fucoproteomic profiling of CD4 T cells

2022-12-16 | PXD038636 | Pride